


CLAIMS:

1. A pamoate salt of a 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione of Formula I:



wherein:

R_1 represents methoxy, ethoxy or hydroxy;


R_2 represents methoxy, ethoxy, hydroxy or hydrogen; and

n represents 2 or 3,

or a pharmacologically acceptable solvate thereof.

2. A pamoate salt as claimed in Claim 1, wherein R_1 represents methoxy and R_2 represents methoxy or hydrogen.
3. A pamoate salt as claimed in Claim 2, wherein the pamoate salt is 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.
4. A pamoate salt as claimed in Claim 2, wherein the pamoate salt is 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.
5. A pamoate salt as claimed in any one of the preceding claims, wherein the pamoate salt is in the form of its (-) isomer.
6. A pamoate salt as claimed in any one of the preceding claims, wherein the pamoate salt in the form of a hydrate.
7. A pharmaceutical composition comprising a pamoate salt of a 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione of Formula I:

-12-



wherein:

R_1 represents methoxy, ethoxy or hydroxy;

R_2 represents methoxy, ethoxy, hydroxy or hydrogen; and

n represents 2 or 3,

or a pharmacologically acceptable solvate thereof

and a pharmacologically acceptable diluent or carrier.

8 A pharmaceutical composition as claimed in Claim 7 for the treatment or prophylaxis of a stress-related affective disorder.


9 A pharmaceutical composition as claimed in Claim 7 or Claim 8, wherein the 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione is as defined in any one of Claims 2, 5 and 6.

10. A pharmaceutical composition as claimed in Claim 9, wherein the pamoate salt is 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

11. A pharmaceutical composition as claimed in Claim 9, wherein the pamoate salt is 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

12. A pamoate salt of a 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione of Formula I:

-13-



wherein:

R_1 represents methoxy, ethoxy or hydroxy;

R_2 represents methoxy, ethoxy, hydroxy or hydrogen; and

n represents 2 or 3,

or a pharmacologically acceptable solvate thereof

for use in treatment of the human or animal body by therapy or diagnosis practised on the human or animal body.


13 A pamoate salt as claimed in Claim 12, wherein the 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione is as defined in any one of Claims 2, 5 and 6.

14. A pamoate salt as claimed in Claim 13, wherein the pamoate salt is 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

15. A pamoate salt as claimed in Claim 13, wherein the pamoate salt is 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

16. Use of a pamoate salt of a 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione of Formula I:

-14-



wherein:

R_1 represents methoxy, ethoxy or hydroxy;

R_2 represents methoxy, ethoxy, hydroxy or hydrogen; and

n represents 2 or 3,

or a pharmacologically acceptable solvate thereof

in the manufacture of a medicament for the treatment or prophylaxis of stress-related affective disorders.

17. The use as claimed in Claim 16, wherein the stress-related affective disorder is selected from agoraphobia; anorexia nervosa; anxiety; anxiogenesis associated with withdrawal from drugs of abuse; bulimia nervosa; chronic paroxysmal hemicrania; depression (including prevention of depressive recurrences); diminution of the immune response associated with anxiety, depression or bereavement; disorders of sleep initiation or maintenance; disorders of the sleep-awake schedule; dream anxiety attacks; Huntington's chorea; Kleine-Levin syndrome; memory disturbance; Ménière's disease, menstrual-associated sleep syndrome; migraine; motion sickness; nausea incompletely relieved by 5HT₃ antagonist administration, neurogenic pain; neuropathic pain; obsessive-compulsive disorder; panic attacks; posttraumatic stress disorder; premenstrual dysphoric disorder; recurrent brief depression; Restless Leg syndrome, schizophrenia; senile dementia; serotonin-irritation syndrome; sleep apnoea; sleep related cardiovascular symptoms; sleep related epileptic seizures; sleep-related cluster headaches; sleep-related myoclonus syndrome; social phobia; sudden infant death syndrome; and tinnitus.

18. The use as claimed in Claim 17, wherein the medicament is for the treatment or prophylaxis of anxiety.

19. The use as claimed in Claim 17, wherein the medicament is for the treatment or prophylaxis of depression.

20. The use as claimed in Claim 17, wherein the medicament is for the treatment or prophylaxis of migraine.


21. The use as claimed in Claim 17, wherein the medicament is for the treatment or prophylaxis of sleep apnoea.

22. The use as claimed in any one of Claims 16 to 21, wherein the 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione is as defined in any one of Claims 2, 5 and 6.

23. The use as claimed in Claim 22, wherein the pamoate salt is 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

24. The use as claimed in Claim 22, wherein the pamoate salt is 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

25. A method for the treatment or prophylaxis of a stress-related affective disorder which comprises administering to a human or animal patient an effective amount of a pamoate salt of a 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione of Formula I:



wherein:

R₁ represents methoxy, ethoxy or hydroxy;

R₂ represents methoxy, ethoxy, hydroxy or hydrogen; and

n represents 2 or 3,

or a pharmacologically acceptable solvate thereof.

26. A method as claimed in Claim 25, wherein the stress-related affective disorder is selected from the group consisting of agoraphobia; anorexia nervosa; anxiety; anxiogenesis associated with withdrawal from drugs of abuse; bulimia nervosa; chronic paroxysmal hemicrania; depression (including prevention of depressive recurrences); diminution of the immune response associated with anxiety, depression or bereavement; disorders of sleep initiation or maintenance; disorders of the sleep-awake schedule; dream anxiety attacks; Huntington's chorea; Kleine-Levin syndrome; memory disturbance; Ménière's disease, menstrual-associated sleep syndrome; migraine; motion sickness; nausea incompletely relieved by 5HT₃ antagonist administration, neurogenic pain; neuropathic pain; obsessive-compulsive disorder; panic attacks; posttraumatic stress disorder; pre-menstrual dysphoric disorder; recurrent brief depression; Restless Leg syndrome, schizophrenia; senile dementia; serotonin-irritation syndrome; sleep apnoea; sleep related cardiovascular symptoms; sleep related epileptic seizures; sleep-related cluster headaches; sleep-related myoclonus syndrome; social phobia; sudden infant death syndrome; and tinnitus.

27. A method as claimed in Claim 26, wherein the stress-related affective disorder is anxiety.

28. A method as claimed in Claim 26, wherein the stress-related affective disorder is depression.

29. A method as claimed in Claim 26, wherein the stress-related affective disorder is migraine.

30. A method as claimed in Claim 26, wherein the stress-related affective disorder is sleep apnoea.

31. A method as claimed in any one of Claims 25 to 30, wherein the 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione is as defined in any one of Claims 2, 5 and 6.

32. A method as claimed in Claim 31, wherein the pamoate salt is 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

33. A method as claimed in Claim 31, wherein the pamoate salt is 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.